Le Lézard
Classified in: Ebola virus, Health, Covid-19 virus
Subjects: SVY, MRR

Global Cell & Gene Therapy Manufacturing Services Market Research Report 2023


DUBLIN, Feb. 10, 2023 /PRNewswire/ -- The "Cell & Gene Therapy Manufacturing Services Market Report 2023" has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

The global cell & gene therapy manufacturing services market size is projected to reach USD 11.5 billion by 2027 from USD 5.1 billion in 2022, at a CAGR of 17.5%

Growth in this market can be attributed to rapidly increasing private equity and capital investment in life sciences over the last decade coupled with significant investment in cell and gene therapy companies. This is expected to increase the demand for outsourcing, thereby increasing the growth of cell and gene therapy manufacturing services.

Autologous segment accounted for the second largest cell therapy segment market share

The autologous sub segment of the cell therapy segment accounted for the second largest market share. The growth of the autologous segment is attributed to the low risk of post-treatment complications compared to allogeneic stem cell therapy, the increasing number of clinical trials based on autologous types, and an increasing preference for autologous cell therapy in high-income countries.

Infectious diseases segment accounted for the highest CAGR

The infectious diseases segment accounted for the highest CAGR over the forecast period. Despite current drugs and treatments for infectious diseases, HIV/Aids, tuberculosis, coronavirus, Ebola virus, malaria, and respiratory tract diseases form a major concern globally.

According to the Global Tuberculosis report, nearly 10 million people fall ill with tuberculosis (TB) each year. The spread of the COVID-19 pandemic has led to an increase in clinical trials for the development of cell therapies used in the treatment of coronavirus. This is expected to drive the segment growth.

Asia Pacific: The fastest-growing country in the cell & gene therapy manufacturing services market

The Asia Pacific offers lucrative growth potential for the cell & gene therapy manufacturing services market. This can be attributed to improved treatment techniques, the optimization of medical measures, improved medical service quality, and the dynamic adjustment of medical insurance access in countries like China.

Further, high R&D expenditure by pharmaceutical companies in nations like Japan is expected to support drug development research, which will drive the growth of the cell & gene therapy manufacturing services market in the region.

Key Metrics

Premium Insights

Market Dynamics

Drivers

Restraints

Opportunities

Challenges

Company Profiles

Key Market Players

Other Players

For more information about this report visit https://www.researchandmarkets.com/r/hqrj2e-and-gene?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 02:15
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a...

at 02:00
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwardsProvides Novavax with cash and an equity investment totalling approximately $1.2 billion...

9 mai 2024
Star Asia Group is pleased to announce that it has entered into a share transfer agreement with Minacia Co., Ltd. ("Minacia") on April 26, 2024, to acquire 100% of the shares of Minacia. 1? Reason for Share Acquisition Star Asia Group believes that...

9 mai 2024
In the Company's announcement dated May 9, 2024, the 2023 comparative year EBITDA was corrected from $33.2 million to $44.8 million. The complete correct press release follows: Q1 2024 Financial Highlights(1): Revenues of $602.5 millionGross Margin...

9 mai 2024
Afya Limited ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three-month period ended March 31, 2024 (first quarter 2024)....

9 mai 2024
Source Energy Services Ltd. ("Source" or the "Company") is pleased to announce its financial results for the three months ended March 31, 2024. Q1 2024 PERFORMANCE HIGHLIGHTS Key achievements for the quarter ended March 31, 2024 include the...



News published on and distributed by: